Crystal form B of 1-isobutyryl-1′-((1-(4,4,4-trifluorobutyl)-4,5,6,7-tetrahydro-1H-benzo[d]imidazol-2-yl)methyl)spiro[azetidine-3,3′-indolin]-2′-one

US10633347B2 · kind B2 · utility

Assignee

• SHANDONG DANHONG PHARMACEUTICAL CO., LTD. · CN

Inventors

• Weihua Shi · 红钢城街道, CN
• Feng Xu · Durham, US
• Zheng Wang · 安丰镇, CN
• Weidong Li · Cupertino, US
• Linghui Wu · Shanghai, CN
• Hongwei Li · Burnaby, CA
• Minggao Zeng · Shanghai, CN
• Kunmin Lai · Shanghai, CN
• Zhigan Jiang · Shanghai, CN
• Haiying He · Shanghai, CN

Key dates

• Filing date: Jan 8, 2019
• Grant date: Apr 28, 2020
• Expiry date: Jan 8, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Chemical engineering
• WIPO sector: Chemistry

Abstract

Disclosed are a method for preparing an imidazole derivative and crystal form A and crystal form B thereof, and also disclosed is a method for preparing a compound of formula (I) and an intermediate thereof.